NO20034524L - 5-membered heterocycles, preparation and use thereof as MAO inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as drugs. - Google Patents

5-membered heterocycles, preparation and use thereof as MAO inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as drugs.

Info

Publication number
NO20034524L
NO20034524L NO20034524A NO20034524A NO20034524L NO 20034524 L NO20034524 L NO 20034524L NO 20034524 A NO20034524 A NO 20034524A NO 20034524 A NO20034524 A NO 20034524A NO 20034524 L NO20034524 L NO 20034524L
Authority
NO
Norway
Prior art keywords
preparation
inhibitors
drugs
lipid peroxidation
membered heterocycles
Prior art date
Application number
NO20034524A
Other languages
Norwegian (no)
Other versions
NO326051B1 (en
NO20034524D0 (en
Inventor
Alain Rolland
Jeremiah Harnett
Dennis Bigg
Anne-Marie Liberatore
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0104943A external-priority patent/FR2823208B1/en
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20034524D0 publication Critical patent/NO20034524D0/en
Publication of NO20034524L publication Critical patent/NO20034524L/en
Publication of NO326051B1 publication Critical patent/NO326051B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
NO20034524A 2001-04-10 2003-10-09 5-membered heterocycles, drug and its use, as well as pharmaceutical preparation. NO326051B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104943A FR2823208B1 (en) 2001-04-10 2001-04-10 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
FR0201811 2002-02-14
PCT/FR2002/001218 WO2002083656A2 (en) 2001-04-10 2002-04-09 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments

Publications (3)

Publication Number Publication Date
NO20034524D0 NO20034524D0 (en) 2003-10-09
NO20034524L true NO20034524L (en) 2003-10-29
NO326051B1 NO326051B1 (en) 2008-09-08

Family

ID=26212970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034524A NO326051B1 (en) 2001-04-10 2003-10-09 5-membered heterocycles, drug and its use, as well as pharmaceutical preparation.

Country Status (23)

Country Link
EP (1) EP1379514B1 (en)
JP (1) JP4422964B2 (en)
KR (1) KR100865809B1 (en)
CN (1) CN1284777C (en)
AR (1) AR036329A1 (en)
AU (1) AU2002307980B2 (en)
BR (2) BRPI0208703B1 (en)
CA (1) CA2443403C (en)
CZ (1) CZ304550B6 (en)
DE (1) DE60232959D1 (en)
ES (1) ES2328467T3 (en)
HK (1) HK1070055A1 (en)
HU (1) HU228192B1 (en)
IL (2) IL158121A0 (en)
IS (1) IS2724B (en)
MX (1) MXPA03009194A (en)
MY (1) MY142094A (en)
NO (1) NO326051B1 (en)
NZ (1) NZ528645A (en)
PL (1) PL211939B1 (en)
RU (1) RU2288224C2 (en)
TW (1) TWI248438B (en)
WO (1) WO2002083656A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CA2469228A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
KR20050119201A (en) * 2003-04-09 2005-12-20 니뽄 다바코 산교 가부시키가이샤 Heteroaromatic pentacyclic compound and medicinal use thereof
PT1470818E (en) * 2003-04-25 2006-11-30 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
FR2888116A1 (en) * 2005-07-08 2007-01-12 Sod Conseils Rech Applic THIAZOLE DERIVATIVES FOR TREATING DYSKINESIES
EP1806819A1 (en) * 2006-01-05 2007-07-11 Constructions Electroniques + Telecommunications, en abrégé "C.E.+T" Backup power system
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
AU2012328034B2 (en) * 2011-10-26 2015-04-23 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
CN113831360A (en) * 2021-09-10 2021-12-24 中钢集团南京新材料研究院有限公司 Method for synthesizing 1-carbazole-boronic acid pinacol ester through amide ortho-oriented boronation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
JP2941950B2 (en) * 1994-11-23 1999-08-30 ニューロゲン コーポレイション Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; a novel class of dopamine receptor subtype specific ligands
EP0891358A1 (en) * 1995-10-11 1999-01-20 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
WO1998027108A2 (en) * 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
FR2764889B1 (en) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR9812857A (en) * 1997-10-06 2000-08-08 Lilly Co Eli Compounds useful as neuroprotective agents
CA2335339A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .beta.-carboline compounds
US6414011B1 (en) * 1999-03-26 2002-07-02 Euro-Celtique S.A. Aryl substituted pyrazoles, and pyrroles, and the use thereof
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof

Also Published As

Publication number Publication date
HUP0303799A3 (en) 2008-03-28
PL372297A1 (en) 2005-07-11
NZ528645A (en) 2004-11-26
CZ304550B6 (en) 2014-07-02
AR036329A1 (en) 2004-09-01
KR20030094333A (en) 2003-12-11
JP4422964B2 (en) 2010-03-03
DE60232959D1 (en) 2009-08-27
JP2004531526A (en) 2004-10-14
PL211939B1 (en) 2012-07-31
HU228192B1 (en) 2013-01-28
MXPA03009194A (en) 2004-02-17
IL158121A0 (en) 2004-03-28
CZ20033054A3 (en) 2004-05-12
CA2443403C (en) 2011-09-20
IS6979A (en) 2003-10-08
BR0208703A (en) 2006-02-21
KR100865809B1 (en) 2008-10-28
TWI248438B (en) 2006-02-01
CA2443403A1 (en) 2002-10-24
ES2328467T3 (en) 2009-11-13
RU2288224C2 (en) 2006-11-27
HUP0303799A2 (en) 2004-03-01
CN1535267A (en) 2004-10-06
CN1284777C (en) 2006-11-15
EP1379514A2 (en) 2004-01-14
NO326051B1 (en) 2008-09-08
EP1379514B1 (en) 2009-07-15
NO20034524D0 (en) 2003-10-09
WO2002083656A2 (en) 2002-10-24
IS2724B (en) 2011-03-15
HK1070055A1 (en) 2005-06-10
MY142094A (en) 2010-09-15
BRPI0208703B1 (en) 2017-12-12
IL158121A (en) 2010-04-15
RU2003132471A (en) 2005-01-27
AU2002307980B2 (en) 2007-06-21
WO2002083656A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
DK1953162T3 (en) Xanthine derivatives, their preparation and their use as a drug.
NO20021689L (en) 5-membered heterocyclic derivatives, their preparation and use as drugs
NO20035298D0 (en) CDK-inhibiting pyrimides, their preparation and their use as drugs
NO20042084L (en) 6-hydroxyisoflavones, derivatives and drugs comprising them
NO20042635L (en) 5-Sulfanyl-HH-1,2,4-triazole derivatives and their use as medicine
ITTO20010005A0 (en) PHARMACEUTICAL FORMULATION.
DK1445252T3 (en) Sulfonamide derivatives, their preparation and use as drugs
NO20025879L (en) Acylphenylurea derivatives, processes for their preparation and their use as a drug
NL1015859A1 (en) Pharmaceutical preparations.
ATE370120T1 (en) SUBSTITUTED 2-PYRIDINE-CYCLOHEXANE-1,4-DIAMINE DERIVATIVES
NO20033556D0 (en) Pharmaceutical preparations
EE200300311A (en) Phthalazinone-piperidine derivatives, their use and medicine
DK1095025T3 (en) Benzimidazoles, their preparation and their use as drugs
DK1500654T3 (en) Benzoxazinone derivatives, their preparation and their use as pharmaceuticals
HK1070055A1 (en) 5-Membered heterocycles, preparation and application thereof as medicaments
DE50209245D1 (en) NEUROPROTEKTIVES MEDICAMENT
DK1417189T3 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
DK1387838T3 (en) Cyanoanthranylamide derivatives and their use as drugs
DE60203537D1 (en) 5HT1-RECEPTORAGONIST-CONTAINING MEDICAMENT
NO20034647L (en) Hydroxyclylalkoxy, alkyloxy and alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
NO20040702L (en) Combined preparations containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances and the use thereof
AU2002307980A1 (en) 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments
NO20033120D0 (en) 2-arylimino-2,3-dihydrotiazole derivatives, processes for their preparation and therapeutic use thereof
DK1532141T3 (en) 2-Pyrrolidin-2-yl [1,3,4] oxadiazole derivatives and their use as antidepressants
NO20033697L (en) Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees